Ikena Oncology, Inc. (IKNA)

NASDAQ: IKNA · IEX Real-Time Price · USD
2.43
+0.01 (0.41%)
Nov 29, 2022 4:00 PM EDT - Market closed
0.41%
Market Cap 87.74M
Revenue (ttm) 30.38M
Net Income (ttm) -51.87M
Shares Out 36.26M
EPS (ttm) 0.80
PE Ratio 3.04
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 111,288
Open 2.5
Previous Close 2.42
Day's Range 2.24 - 2.76
52-Week Range 1.94 - 16.95
Beta n/a
Analysts Buy
Price Target 24.82 (+921.4%)
Earnings Date Nov 9, 2022

About IKNA

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antag... [Read more]

Industry Biotechnology
IPO Date Mar 26, 2021
Employees 78
Stock Exchange NASDAQ
Ticker Symbol IKNA
Full Company Profile

Financial Performance

In 2021, Ikena Oncology's revenue was $30.99 million, an increase of 237.01% compared to the previous year's $9.19 million. Losses were -$34.12 million, -22.91% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for IKNA stock is "Buy." The 12-month stock price forecast is 24.82, which is an increase of 921.40% from the latest price.

Price Target
$24.82
(921.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023

1 day ago - GlobeNewsWire

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that manag...

1 week ago - GlobeNewsWire

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma

2 weeks ago - GlobeNewsWire

Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab

3 weeks ago - GlobeNewsWire

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab

3 weeks ago - GlobeNewsWire

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combat...

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a poster p...

1 month ago - GlobeNewsWire

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers

1 month ago - GlobeNewsWire

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immuno...

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two a...

1 month ago - GlobeNewsWire

Ikena Oncology to Participate in September 2022 Investor Conferences

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that mana...

2 months ago - GlobeNewsWire

Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -18.75% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Advancement across Company's pipeline towards regulatory and data milestones Advancement across Company's pipeline towards regulatory and data milestones

3 months ago - GlobeNewsWire

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that Mark ...

4 months ago - GlobeNewsWire

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficien...

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U...

5 months ago - GlobeNewsWire

Ikena Oncology to Participate in Spring 2022 Investor Conferences

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that manage...

6 months ago - GlobeNewsWire

Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary anti-tumor activity

6 months ago - GlobeNewsWire

Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season?

Ikena Oncology (IKNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Other symbols: ANGNAPLTBOLTLABP
6 months ago - Zacks Investment Research

Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, a...

6 months ago - Business Wire

Ikena Oncology and Vall d'Hebron Institute of Oncology Announce Research & Development Collaboration

Partnership will enable generation of tumor and biomarker-specific data to broaden Ikena's and VHIO's leadership in research, translational science, and development of targeted oncology therapies Partne...

6 months ago - GlobeNewsWire

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it w...

7 months ago - GlobeNewsWire

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & development Dr. Marango brings years of valued experience in oncology biopharma business,...

7 months ago - GlobeNewsWire

Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024

8 months ago - GlobeNewsWire

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for...

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it will pa...

8 months ago - GlobeNewsWire